000148191 001__ 148191
000148191 005__ 20250115151521.0
000148191 0247_ $$2doi$$a10.1016/j.ijpharm.2018.12.062
000148191 0248_ $$2sideral$$a135586
000148191 037__ $$aART-2018-135586
000148191 041__ $$aeng
000148191 100__ $$aCañibano-Hernández, Alberto
000148191 245__ $$aHyaluronic acid enhances cell survival of encapsulated insulin-producing cells in alginate-based microcapsules
000148191 260__ $$c2018
000148191 5060_ $$aAccess copy available to the general public$$fUnrestricted
000148191 5203_ $$aPancreatic islet transplantation has proved to be a promising therapy for T1DM, in spite of the chronic immunosuppression required. Although cell microencapsulation technology represents an alternative to circumvent the immune system rejection of transplanted pancreatic islets, the environment provided by classical alginate microcapsules does not mimic the natural ECM, affecting the islet survival. Since hyaluronic acid, one of the major components of pancreatic ECM, is involved in cell adhesion and viability, we assessed the beneficial outcomes on encapsulated insulin-producing cells by the HA inclusion in alginate matrices. In this manuscript we describe how alginate-HA hybrid microcapsules enhance the viability of encapsulated cells, reducing early apoptosis percentage and decreasing membrane damage. A stable insulin production was maintained in encapsulated cells, not altering the response to a glucose stimulus. Therefore, we can conclude that the inclusion of HA within alginate microcapsules is beneficial for encapsulated insulin-producing cells, representing a step forward in the clinical translation of microcapsules technology for the treatment of T1DM.
000148191 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc-nd$$uhttp://creativecommons.org/licenses/by-nc-nd/3.0/es/
000148191 590__ $$a4.213$$b2018
000148191 591__ $$aPHARMACOLOGY & PHARMACY$$b44 / 266 = 0.165$$c2018$$dQ1$$eT1
000148191 592__ $$a1.135$$b2018
000148191 593__ $$aPharmaceutical Science$$c2018$$dQ1
000148191 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/acceptedVersion
000148191 700__ $$aSaenz del Burgo, Laura
000148191 700__ $$aEspona-Noguera, Albert
000148191 700__ $$aOrive, Gorka
000148191 700__ $$aHernández, Rosa Mª
000148191 700__ $$0(orcid)0000-0002-8666-622X$$aCiriza, Jesús
000148191 700__ $$aPedraz, Jose Luis
000148191 773__ $$g557 (2018), 192-198$$pInt. j. pharm.$$tInternational Journal of Pharmaceutics$$x0378-5173
000148191 8564_ $$s507269$$uhttps://zaguan.unizar.es/record/148191/files/texto_completo.pdf$$yPostprint
000148191 8564_ $$s1160832$$uhttps://zaguan.unizar.es/record/148191/files/texto_completo.jpg?subformat=icon$$xicon$$yPostprint
000148191 909CO $$ooai:zaguan.unizar.es:148191$$particulos$$pdriver
000148191 951__ $$a2025-01-15-15:14:39
000148191 980__ $$aARTICLE